Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Warrant holders are still screwed." .. ADXS shareholders are also screwed.
"Yep, they can't have more than one......not allowed" .. Yep, Amgen doesn't want more than one from ADXS.
"One deal from Amgen, this could run like a monster!" ... Problem is, Amgen already has the only deal it wants from ADXS.
"The interesting thing is the BOD and Mgt purchased the shares they did in the $1.80 range." ... Just proves what a bunch of incompetent bozos the BOD & Mgt are.
"The lower the share price goes, the fewer options Ken & the BOD have to move the company forward in a way that makes any .sense."....Berlin will take the only option available to him & that will be ANOTHER monster reverse split that will wipe out all current ADXS shareholder value.
I posted many times that AXAL was a dud & will not get FDA or EU approval. Con man Ken Berlin also knows it & that why he will cut off the funds to continue the AXAL trials when he fails to find any entity that will put up big time cash for AXAL. All other BP knows that Amgen, who knows more about ADXS than any other BP ever will, wants no part of AXAL even for what would be peanuts for Amgen.
"You mean like Amgen paying $500 million for pre-clinical NEO at an even earlier stage?" Amgen isn't making any offers for HOT or simply buying ADXS for peanuts & owning NEO, HOT & AXAL. Three for the price of one. How could Amgen resist such an opportunity?
Lots of noise on this board about an up front big time cash deal to partner for HOT. Why would any BP do a cash deal for HOT which is totally unproven, over hyped & hasn't even started any FDA trials, when BP could do a big time cash deal to partner for AXAL which is now in phase 3 trials & offers far less risk & much better odds of success than HOT? However, no BP wants to put up big time cash to partner for AXAL, chances are no BP will want to give big time cash to ADXS for nothing but a speculative, over hyped, unproved HOT.
" My buddy says they`d rather pay 5 times more for a proven concept,then pay chump for it prematurely.".. Your buddy is a very dim bulb.
"If HOT is hot, "forget about it"... If HOT is not, "forget about it"
"Thus, it is not hard to see this as a motivating factor for an Amgen buyout, in addition to its saving of the $450 in milestones, plus future royalties, not to mention acquiring all rights to HOT, AXAL, PSA, etc." ...I have posted many times before that it is an ominous red flag that Amgen has not bought out ADXS while it can buy ADXS for what to Amgen is peanuts. I was attacked for posting what is obvious to Amgen & now obvious even to the ADXS bag holders & dreamers. For Amgen, very low financial risk with the possibility that NEO could be a big winner. In addition, I posted that Amgen would also own HOT, AXAL & PSA. Four for the price of one, seems like a no brainer to me. However, Amgen did not make any move to buy out ADXS which Amgen could have done, but hasn't. Very ominous red flag for the ADXS share price.
"No, it will take until 2021, with a primary completion date in 2020." ... What is the primary completion date for NEO & HOT?
"No—AIM2CERV is projected to report the primary endpoint (DFS) in Jun 2020, according to clinicaltrials.gov " ... What is the projected year that NEO & HOT will get to the same primary endpoint {DFS}?
"Algo games still being played to keep the SP suppressed" ...Those playing the "Algo games" must be the dumbest donkeys on the face of the earth. Assuming these "algo games" players have the ability to suppress the share price, they could also use their "Algo games" to explode the stock to the up side & could makes tons more money moving the stock up rather than wasting capital suppressing a stock trading at $1.71.
"This is not quite right. They stated that if they cannot identify a commercialization plan, then this is the strategy they will enact, rather than continue with the some 5-10 million in expense per quarter on a trial that needs several years yet" ... Berlin will stop the phase 3 AXAL trials after spending millions of shareholders capital & years of time if he can't find a cash partner or sell AXAL outright because of AXAL ongoing trial expense. Berlin trades AXAL which is in phase 3 trials so he can spend more multi millions of shareholder money to start new trials for NEO & HOT which will take much more time & expense than continuing to fund the AXAL trials. Why would Berlin dump AXAL, which IF AXAL is the real deal will get to market several years before NEO & HOT possibly could because NEO & HOT are still several years away from even completing trials? The reason is Berlin knows AXAL is a dud so he traded AXAL in phase 3 trials for NEO & Hot which are just starting phase 1 trials.
"Amgn needs to control HOT".. You proved my point. IF Amgen NEEDS to control HOT the only way Amgen could be assured of control is to buy out ADXS now, not for billions at a later date, but right now when it could buy ADXS for what to Amgen is peanuts & control HOT, NEO, AXAL & PSA.
"HOT will have major licensing deals with multiple partners or Amgn will buy the company to avert that from happening. Amgn needs the HOT and can`t afford to let anyone else get it." Then why hasn't Amgen bought ADXS now for absolute peanuts & they could own not only HOT but NEO, AXAL & PSA also?
"Why would AMGN buy it for NEO when they already have rights to NEO and only have to pay the milestones and royalties if the product is successful?".. Because if Amgen bought out ADXS now for peanuts it would not pay any milestones or royalties & all profits generated by NEO would be in their pocket & Amgen would also have HOT & AXAL for free.
Ken Berlin, the con man CEO. Ever since it's inception, AXAL was highly hyped & is the lead product that was going to cure cervical cancer. Million of shareholder dollars were spent on pre clinical & FDA clinical trials. Analyst covering ADXS had share price targets between $20 & $30. Many zero cash partnerships were completed for AXAL in Asia. South America, etc. ADXS even built a manufacturing facility for AXAL. Every shareholder who gambled in ADXS did so because they believed the hype of the Listeria science, that AXAL was the real deal & would be brought to market after the AXAL phase 3 FDA trials that are currently ongoing were completed & FDA approved AXAL . Now comes new ADXS CEO, con man Ken Berlin & the first thing he does is throw AXAL under the bus because Berlin knows, as did I, the shorts & all BP that AXAL is a dud. Berlin is now looking to dump AXAL & get what ever he can for it. All ADXS shareholders were shocked to find out AXAL was being dumped. To justify this radical change, con man Ken Berlin started the hype campaign for NEO & HOT. Berlin, a master snake oil salesman, hyped NEO as being the next generation product that was the hottest new thing since AXAL. The ADXS dreamers bought this hype hook line & sinker & thought that the ADXS share price would explode. That didn't happen. Berlin then announced the first NEO patient was dosed & again the ADXS dreamers were jubilant that the share price would explode but once again the market wasn't buying Berlin's NEO & HOT hype. After a very small pop, ADXS is still trading near all time lows. One analyst now has a $2 share price target for ADXS, a far cry from the previous $20 to $30 price targets. The market is not buying the NEO & HOT hype, just as it didn't buy the AXAL hype. ADXS dreamer, should all ask themselves if con man Ken Berlin was right about the NEO & HOT hype, why has not Amgen, who has a lock on NEO, not bought out ADXS now for peanuts & it could have not only NEO, but also HOT & the dumped AXAL?
Toxic floorless convertible debt financing, for those who don't know, is exactly the debt financing that Bertsos used to finance BSTN.....What is a Toxic Funding
A toxic financing is convertible debt or preferred stock that allows the financier, the holder of the debt or preferred shares, to essentially receive an unlimited number of free trading common shares when they convert their debt or preferred shares to common stock. The debt or preferred shares carry an interest or dividend rate that the company is usually unable to pay; and as a result the financier converts the shares into common shares that they then sell into the market in order to be repaid and earn a profit on the investment. The formula for the conversion into common shares is structured so that there is no downside limit on the price received for the converted shares. This is what is known as a “floorless convertible” and this is what makes the financing or funding toxic.
These convertible preferred and convertible debts usually convert into common shares based upon a formula (“floating conversion rate“) that is effectively a discount to the market price of the shares at the time of the conversion. For example in the early days of these types of convertible instruments, the formula might call for the conversion of the debt or preferred shares into common shares at a 20% discount to the market price on the day of conversion. Therefore the language in the contract might say something “has the right to convert into common shares at a price equal to 80% of the closing price.” Now as the participants in the market have gotten more sophisticated, and the language in the contracts has gotten a lot more sophisticated as well. Now there are a whole host of clauses and provisions that take into account the price weighted volume, the average price over a several day period of time, lowest price over a period of time. The conversion clauses have become far more complicated, and far more difficult for the average person to understand. It is easy to see how these clauses can get past people who really do not understand what they are reading.
It should be noted that a conversion clause with a floor would read something like “the greater of $2.00 per share, or 80% of the market price…” With this language in a conversion clause, the lowest price at which the convertible debt or convertible preferred can be converted into common shares is $2.00 per share. This conversion clause actually has two (2) types of provisions in it. The 1st being the hard conversion price of $2.00 per share. The 2nd being the floating conversion rate of a 20% discount (80% of the market price) from the market price. The “greater of” language establishes the hard conversion price of $2.00 per share as the floor price of any conversions.
What Happens in a Toxic Funding
The vast majority of small and micro cap company Presidents and Chief Financial Officers (CFO) are not familiar with the term toxic financing, and even less understand what happens if they undertake a toxic financing. As a result it is important to understand what happens once a company engages in a toxic financing.
The form of the contract or funding agreement can vary greatly from one toxic funder to the next. However, once the agreement has been signed, usually some money is provided to the company. There is now a debt or convertible preferred that can be converted into free trading common shares one of three ways. The methods of obtaining free trading shares are either through the registration statement filed with the SEC, a court order, or Rule 144 exemption. We will take a greater look at these methods of obtaining free trading shares in a later article. However, what is important is that within a short period of time, the company now has a convertible instrument on its balance sheet that can be converted into free trading shares.
In the vast majority of instances, the companies that enter into these toxic funding agreements have a very limited amount of market liquidity for their shares. As a result, when the conversion notice arrives, and the debt or preferred is converted into common shares, the owner of the toxic debt receives free trading shares that are deposited into a brokerage account and sold into the market. This selling almost always drives the price of the stock lower.
One might be tempted to think at this point that it over and done with; that they have converted their debt or preferred and moved on. However, it does not work that they. The toxic financiers are smart. They are only going to convert a fraction of their debt or preferred into common shares. They are only going to look convert a portion of their holdings into shares. Their goal is to convert and sell as many shares as they can above the conversion price, before their selling drives the stock price below the conversion price. As a result, the conversion notices trickle in, and the stock price continues to move lower, and lower. Think of it as a death by a thousand cuts.
Each subsequent conversion, will be for a greater number of shares, even as the dollar amount being converted remains the same or declines. When this starts to happen, two other important things begin to happen. The 1st being the number of shares issued and outstanding begins to sky rocket. The 2nd being the existing shareholders are massively diluted in their existing holdings. It is not uncommon for some companies that have engaged in a toxic financing to see the number of shares they have issued and outstanding go from less than 50 million to over 5 billion.
These toxic fundings also shut off a company’s access to more legitimate fund raising sources.
During the conference call, will Berlin have the balls to take questions from retail investors who will ask all the pertinent hard ball questions or will Berlin only take soft ball questions from the bozo analysts on the call? We shall see what Berlin is made.
More lame excuses for the collaspe of the share price. Lol
What will happen is mass dilution, either before or after another reverse split which will wipe out all current ADXS bag holders money that they wasted in this garbage stock.
A fool & his money are soon parted.
BSTN dreamers hear what they want to hear & disregard the rest. Lol.
Wait until Bertsos trys to obtain funding. Then you will see what a liar Bertsos is.
"Probably they will reverse and then dilute in order to finance the acquisition".. Correct, Bertsos will have to do another monster reverse split which will destroy current shareholder value ASSUMING Bertsos can get funding with the monster amount floorless death spiral convertible debt on the books that's still to be converted. Until all the convertible debt is converted, there will be continuous mass dilution foisted on current shareholders causing the share price to continue to decline. A very ugly picture for current shareholders.
"The acquisition of Nuova Abibes is planned to be with a combination of Capital injection to Nuova from Boston and further issuance of some shares from Boston to Nuova’s existing shareholders"..... Where is Bertsos going to get the money to give to Nuovos? Certainly not from the shipping business. Can't float more debt as there is tons of floorless death spiral convertible debt still on the books that will for sure be converted into shares foisting continuing mass dilution on all BSTN shareholders. In addition, how much mass dilution does giving "SOME" shares to Nuova's shareholders cause? Very ominous red flags for all BSTN shareholders.
"The short daytraders are getting very little traction recently." ... The long ADXS bag holders & dreamers have been getting NO traction for years & the worst is yet to come.
" The reverse split will occur before the next BIG dilution.".. Bottom line is that it is inevitable that there will be another monster reverse split before or after Berlin foists more big time mass dilution on all current ADXS bag holders that will be the final nail in their coffins as they lose the money they gambled in this garbage stock
"Shorts are still working it"..LOL
This is what ADXS should have done but did not............
Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D.
PLYMOUTH MEETING, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (INO) today announced that it has bolstered its efforts to attract partnerships and collaborations and increase non-dilutive funding with the hiring of an accomplished business development leader and the promotion of a key R&D leader.
Mr. Shawn D. Bridy joins Inovio as Vice President of Business Development reporting to Dr. J. Joseph Kim, President & CEO. Mr. Bridy has more than 20 years of business development & licensing, commercial strategy, and transaction experience in the life sciences industry. He previously held strategic business development roles at large pharma companies and smaller biotechs including GSK, Elan, BTG plc and Immunome. Most recently he was Managing Director of Bridy Advisors, a top-tier strategic and operational advisory company. Mr. Bridy has an MA in Biology and an MBA in Finance from Villanova University.
Inovio has also promoted Dr. Kate E. Broderick, Ph.D., to Vice President, Preclinical Research & Development reporting to Dr. Laurent Humeau, Senior Vice President, R&D. In her new position, Dr. Broderick will continue to spearhead Inovio’s efforts to secure non-dilutive strategic R&D funding opportunities to support the research and clinical testing of Inovio’s candidate vaccines. Dr. Broderick has previously led Inovio’s efforts to receive numerous grants from the U.S. National Institutes of Health and Department of Defense as well from other government and non-governmental organizations. She recently led Inovio’s efforts to secure a $56 million funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to evaluate DNA vaccine candidates for Lassa fever and MERS through Phase 2 clinical testing. She will also be responsible for the oversight of a diverse preclinical R&D team encompassing discovery and development research, as well as operations, research DNA manufacturing and next-generation device development. She earned her Ph.D. at the University of Glasgow, Scotland.
Dr. Broderick recently participated in World Health Organization (WHO) advisory panel in Geneva on “Product Development & Programmatic Considerations for Nucleic Acid-based Vaccines,” where she highlighted Inovio’s emerging infectious disease vaccine portfolio, which includes the company’s vaccine for Ebola.
Dr. J. Joseph Kim, Inovio’s President & CEO, said, “While we have a strong record of performance in attracting commercial partners such as MedImmune/AstraZeneca, Genentech/Roche and Regeneron and have secured significant non-dilutive funding in the past several years, hiring and promoting these two business and scientific leaders will accelerate and expand those efforts going forward. Kate and Shawn will play important roles in the growth of Inovio as we partner assets and secure funding to support the advancement of Inovio’s immunotherapies and vaccines.”
Mass dilution & another monster reverse split will be the final nail in the ADXS bag holders coffin. There are three ways for Berlin to fund ADXS in the very near future. One way is a buy out. That will not happen even at this miniscule market cap because BP, including Amgen, knows that AXAL is a dud & despite ADXS bag holders begging for years for a buy out, a buy out has not & will not happen. The second way to fund ADXS is a partnership with monster money upfront. This will also not happen as no BP wants any part of AXAL & Amgen has NEO locked up so ADXS has nothing promising for any BP to want to partner with ADXS & put up monster up front money. ADXS already has many "partners" who paid little or nothing upfront to ADXS & ADXS is paying the freight in those useless "partnerships". The third way is the ADXS bag holders worst night mare come true. Mass dilution way under $2 AGAIN. This mass dilution by Berlin will then force ANOTHER monster reverse split which will be the final wipe out of all current ADXS bag holder money that was gambled in this garbage stock.
Zanu PF aims to move Zim from pariah to global partner
May 22 2018 06:32 Crecey Kuyedzwa
Zimbabwe's ruling Zimbabwe African National Union Patriotic Front (Zanu PF) says that if it is re-elected in the forthcoming national polls, it will focus on opening the country for business, fighting corruption and making land productive again.
The country will be holding its national elections between July and August. In its 2018 election manifesto, Zanu PF says it will focus on modernising the public sector and promoting investment.
This will include the merging of six entities to form a one-stop investment centre. In so doing, the Zimbabwean government hopes to reduce the time it takes for investors to get their projects approved as all procedures will be done under one roof.
It will also realign its economic empowerment programme to an investor-friendly trajectory, which it expects will lead to economic growth and employment creation.
The country's empowerment laws have gone through a major shift, including the removal of racially discriminatory drafting.
Business ownership now open to all Zimbabweans
With the introduction of the amendments, business ownership is no longer based on racial lines with reference to indigenous Zimbabweans, but is now open to Zimbabwean citizens irrespective of race.
The party says following the successful execution of “Operation Restore Legacy” and the subsequent inauguration of current President Emmerson Mnangagwa, the new political dispensation will seek to reposition Zimbabwe in its rightful place in the international community.
Under former president Robert Mugabe’s rule, Zimbabwe was regarded by many Western countries as a pariah state. The ruling party says its mission will now be to move the country “from pariah to global partner.”
It says its “socio-economic interventions will include modernising and mechanising agricultural productivity, elimination of multiple farm ownership and reduction of farm sizes, democratic principles and rule of law, and sustaining unity and peace while tolerating each other in our diversity”.
Following the land reform programme embarked upon in 2000, which faced a myriad of challenges, Zanu PF will now focus on productive use of the land and the issuance of security of tenure documents to beneficiaries to allow for long-term security of tenure.
The issue of land tenure has been a contentious one for years, with the newly resettled farmers failing to access funding for lack of security. But the ruling party now says if given a new mandate, it will provide land reform beneficiaries with bankable leasehold security of tenure.
Multiple farm ownership, which is currently rampant, is also expected to be resolved in order to have more people on the land.
“Wider access to land will be achieved through rightsizing of farms and elimination of multiple farm ownership,” says Zanu PF.
Analysts are however still sceptical on whether the ruling party is capable of reform, given that it has been in power for the past 37 years with Mnangagwa one of the key personnel in government.
However, since assuming power in November 2017, Mnangagwa has gone all out to pronounce and make key economic reforms. This includes a major shift in the country’s empowerment laws, as well as advocating for foreign direct investment.
" They haven't reduced the cash burn, they keep hiring, pay generous salaries and bonuses, RSUs, and produce what? Something has to change."... What is going to change is that current ADXS bag holders will be wiped out by the mass dilution that will shortly be foisted on them to raise money. That will be followed by another monster ADXS reverse split. Watch out below current ADXS bag holders & already dead warrant holders, the worst is yet to come.
"In other words, NEO is a ticket potentially worth its weight in gold."... If there is any truth to that statement, Amgen, who knows more about NEO & ADXS than anyone, would have bought ADXS for peanuts any time it wanted, but chose not to.
"Clearly Tony was negotiating deals." This has to be one of the more laughable posts ever posted. There is zero proof or ANY indication that Tony was negotiating any deals. Pure nonsense. If there was any truth to that statement, it would have been reflected in volume & upward price movement of ADXS stock which NEVER happened.
The ADXS garbage continues to torture ADXS shareholders. The market has voted a unanimous thumbs down on the new ADXS management. The only hope that ADXS investors have left is a buy out. Problem is no matter how much the ADXS market cap collapses, no matter how "cheap" a buy out gets, NO buy out. How can this be? Why are zero BP, especially Amgen, not knocking the doors down to buy this ADXS abomination for absolute peanuts? The obvious answer is that BP knows that AXAL is a dud that will not obtain FDA or EU approval. What ADXS investors can take to the bank is that monster mass dilution is very soon to be foisted on all ADXS shareholders who will watch their ADXS money disappear right before their unbelieving eyes.
Once again ADXS displays what a total garbage stock it is. ADXS appoints new management, try's to hype their management skills but the market immediately votes a solid thumbs down on the new ADXS management & the stock is trading near all time LOWS. The only hope the ADXS shareholders have left is for a buy out, which won't happen because BP, especially Amgen, know that AXAL is a dud & will not get FDA or EU approval. In addition the ADXS shareholders will be subject to monster mass dilution in the very near future. ADXS is a very ugly black hole where ADXS shareholder value is destroyed.